A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 201–300 of 1,003
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Paschou, S. A., Polyzos, S. A., Anagnostis, P., Goulis, D. G., Kanaka-Gantenbein, C., Lambrinoudaki, I., Georgopoulos, N. A., & Vryonidou, A. (2020) · Endocrine · doi:10.1007/s12020-019-02085-7 · Cited by 231
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Liu, Q., Bengmark, S., & Qu, S. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-42 · Cited by 229
Metabolic syndrome and non-alcoholic fatty liver disease
Almeda-Valdés, P., Cuevas-Ramos, D., & Alberto Aguilar-Salinas, C. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31822-8 · Cited by 229
Petit, J.-M., Cercueil, J.-P., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 227
“Such a marked decrease in LFC was shown in patients with diabetes who hadNASH, confirmed by examination of biopsy specimens, after 6 months of treatment with pioglitazone, another antidiabetic agent of the thiazolidinedione class, at a dose of 45 mg/d (24).”
Background9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Properzi, C., O'Sullivan, T. A., Sherriff, J. L., Ching, H. L., Jeffrey, G. P., Buckley, R. F., Tibballs, J., MacQuillan, G. C., Garas, G., & Adams, L. A. (2018) · Hepatology · doi:10.1002/hep.30076 · Cited by 227
“1%).(29) Endpoints were analyzed on an intention-totreat basis at study completion (week 12).”
MethodDormandy, J., Bhattacharya, M., & van Troostenburg de Bruyn, A.-R. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Pioglitazone: side effect and safety profile
Shah, P., & Mudaliar, S. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003623218 · Cited by 226
“There is growing data now that non-alcoholic fatty liver diseasemay even be a hepaticmanifestation of Type 2 diabetes and in recent studies, the administration of pioglitazone has been associated with metabolic and histologic improvements in diabetic and non-diabetic study patients with nonalcoholic steatohepatitis [3…”
BackgroundNon-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225
“Pioglitazone primarily targets the PPARγ receptor which ameliorates insulin resistance, an independent predictor of NASH (Belfort et al., 2006).”
BackgroundPioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Self-citationMechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
Kakisaka, K., Cazanave, S. C., Fingas, C. D., Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., Mott, J. L., & Gores, G. J. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00301.2011 · Cited by 222
“Once the critical LPC-mediated pathways for lipotoxicity have been elucidated, rationally designed therapies for NAFLD can hopefully be developed.”
BackgroundInfluentialAfonso, M. B., Rodrigues, P. M., Carvalho, T., Caridade, M., Borralho, P., Cortez-Pinto, H., Castro, R. E., & Rodrigues, C. M. P. (2015) · Clinical Science · doi:10.1042/cs20140732 · Cited by 221
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
Self-citationRosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.031 · Cited by 217
Self-citationMantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
Obstructive Sleep Apnea, Insulin Resistance, and Steatohepatitis in Severe Obesity
Polotsky, V. Y., Patil, S. P., Savransky, V., Laffan, A., Fonti, S., Frame, L. A., Steele, K. E., Schweizter, M. A., Clark, J. M., Torbenson, M. S., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200804-608oc · Cited by 210
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Self-citationAbnormal Hepatic Energy Homeostasis in Type 2 Diabetes†
Szendroedi, J., Chmelik, M., Schmid, A. I., Nowotny, P., Brehm, A., Krssak, M., Moser, E., & Roden, M. (2009) · Hepatology · doi:10.1002/hep.23093 · Cited by 204
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s004 · Cited by 207
“PioglitazoneandvitaminE treatment of biopsy-proven nonalcoholic steatohepatitis have been shown to improve liver histology, but effects on longerterm clinical outcomes are not known (51,52).”
BackgroundNon-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 204
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
“points to measure glucose, insulin, C-peptide, plasma FFA, ketones, and glucagon, as previously described.(27) Indirect calorimetry (Vmax”
MethodSelf-citationBeyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis†
Maher, J. J., Leon, P., & Ryan, J. C. (2008) · Hepatology · doi:10.1002/hep.22399 · Cited by 203
Treatments for NAFLD: State of Art
Mantovani, A., & Dalbeni, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052350 · Cited by 202
Ectopic lipids and organ function.
Szendroedi, J., & Roden, M. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328321b3a8 · Cited by 200
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12511 · Cited by 200
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199
“Nevertheless, improvements in histologic parameters did occur in both groups, implying that pioglitazone’s effect on glycemic control may play less of a role than treatment of insulin resistance in histologic response in NASH.”
InfluentialSelf-citationVuppalanchi, R., Ünalp, A., Van Natta, M. L., Cummings, O. W., Sandrasegaran, K. E., Hameed, T., Tonascia, J., & Chalasani, N. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.12.015 · Cited by 198
Paniagua, J. A. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i19.483 · Cited by 197
Kotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196
Maximos, M., Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Biernacki, D., Suman, A., Weber, M., & Cusi, K. (2015) · Hepatology · doi:10.1002/hep.27395 · Cited by 195
“Liver triglyceride content was measured by proton nuclear magnetic resonance spectra of the liver using a methodology previously described.(12-14,16) In brief, three areas of interest were taken using an echo time/repetition time/flip angle of 30 ms/2,000 ms/90 degrees with a volume of 30 3 30 3 30 mm each.”
MethodSelf-citationTargeting farnesoid X receptor for liver and metabolic disorders
Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E., & Santucci, L. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.06.001 · Cited by 196
Non‐alcoholic fatty liver disease from pathogenesis to management: an update
Musso, G., Gambino, R., & Cassader, M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00657.x · Cited by 196
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
Park, H., Shima, T., Yamaguchi, K., Mitsuyoshi, H., Minami, M., Yasui, K., Itoh, Y., Yoshikawa, T., Fukui, M., Hasegawa, G., et al. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-010-0291-8 · Cited by 195
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, X.-D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A. A., Wong, V. W.-S., Cai, J., Shapiro, M. D., Eslam, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10543-8 · Cited by 194
“Pioglitazone was proven to improve hepatic histology in steatohepatitis patients with and without T2DM and recommended for patients with T2DM and biopsy-proven steatohepatitis [141].”
BackgroundA role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
Skat‐Rørdam, J., Højland Ipsen, D., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13190 · Cited by 192
The peroxisome: still a mysterious organelle
Schrader, M., & Fahimi, H. D. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0396-9 · Cited by 191
“This has also been proven in a placebo-controlled trial with pioglitazone justifying further long-term studies (Belfort et al. 2006).”
ResultStefanovic-Racic, M., Perdomo, G., Mantell, B. S., Sipula, I. J., Brown, N. F., & O'Doherty, R. M. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00497.2007 · Cited by 192
“Agonists of the nuclear receptor PPAR- , such as pioglitazone (6), or activators of PPAR- , such as fenofibrate (39), have been shown to stimulate fatty acid oxidation and decrease liver TG content, raising hope that these compounds may be useful for the treatment of NAFLD.”
BackgroundShibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 191
JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis
Cazanave, S. C., Mott, J. L., Elmi, N. A., Bronk, S. F., Werneburg, N. W., Akazawa, Y., Kahraman, A., Garrison, S. P., Zambetti, G. P., Charlton, M. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022491 · Cited by 191
Schreuder, T. C., Verwer, B. J., Nieuwkerk, C. M. V., & Mulder, C. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2474 · Cited by 191
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Transcriptional Regulation of Bim by FoxO3A Mediates Hepatocyte Lipoapoptosis
Barreyro, F. J., Kobayashi, S., Bronk, S. F., Werneburg, N. W., Malhi, H., & Gores, G. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704391200 · Cited by 190
CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis
Cazanave, S. C., Elmi, N. A., Akazawa, Y., Bronk, S. F., Mott, J. L., & Gores, G. J. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00091.2010 · Cited by 189
“The concentrations of FFA used in the experiments (400 to 800 M) were similar to the fasting FFA plasma concentrations observed in human nonalcoholic steatohepatitis (5, 33).”
ResultNonalcoholic fatty liver disease
Krawczyk, M., Bonfrate, L., & Portincasa, P. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.08.005 · Cited by 187
“[62–65] Treating insulin resistance might even counteract the underlying inflammatory changes observed in NASH.”
BackgroundIncreased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis
Valenti, L., Rametta, R., Dongiovanni, P., Maggioni, M., Ludovica Fracanzani, A., Zappa, M., Lattuada, E., Roviaro, G., & Fargion, S. (2008) · Diabetes · doi:10.2337/db07-0714 · Cited by 187
“0001 IFG/IGT 4 (22) 0* 5 (18)* 13 (50) 0.”
BackgroundPharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Ahmed, M. H., & Byrne, C. D. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.009 · Cited by 186
The Role of Metformin in the Management of NAFLD
Mazza, A., Fruci, B., Garinis, G. A., Giuliano, S., Malaguarnera, R., & Belfiore, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/716404 · Cited by 184
Duseja, A., Singh, S. P., Saraswat, V. A., Acharya, S. K., Chawla, Y. K., Chowdhury, S., Dhiman, R. K., Jayakumar, R. V., Madan, K., Misra, S. P., et al. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.006 · Cited by 186
Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 179
Nonalcoholic fatty liver disease in type 2 diabetes mellitus
Cusi, K. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283293015 · Cited by 185
Self-citationTorres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
“Histopathologic evidence of NASH resolved in 36% of cases, comparable to previous studies with pioglitazone.(8,10) Additionally, improvement in the NAS (71%-77%) was similar to our previous study with pioglitazone(10) and better than an earlier study done with rosiglitazone.”
BackgroundResultSelf-citationSahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876992 · Cited by 180
“Preclinical studies in rodent models of NAFLD/NASH (Western diet-fed human apo-E2 transgenic mice; methionine- and choline-deficient diet-fed db/db mice and CCl4-induced fibrotic rats) consistently demonstrated that GFT-505 treatment decreases hepatic steatosis, inflammation and fibrosis, decreases liver dysfunction b…”
BackgroundInfluentialAmerican Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s004 · Cited by 182
“term clinical outcomes are not known (46,47).”
A fresh look at NASH pathogenesis. Part 1: The metabolic movers
Larter, C. Z., Chitturi, S., Heydet, D., & Farrell, G. C. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06253.x · Cited by 180
MASTERTON, G. S., PLEVRIS, J. N., & HAYES, P. C. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04230.x · Cited by 179
Chew, N. W. S., Mehta, A., Goh, R. S. J., Zhang, A., Chen, Y., Chong, B., Chew, H. S. J., Shabbir, A., Brown, A., Dimitriadis, G. K., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.070535 · Cited by 167
“73 76 A randomized trial of 101 participants with prediabetes or T2D demonstrated 51% of individuals treated with pio-glitazone had MASH resolution, compared to 19% in the placebo arm ( P 0.001), with lower rates of fibrosis progression and reduction in mean fibrosis score.”
InfluentialClinical Syndromes and Consequences of Antiretroviral-Related Hepatotoxicity5, 1, 3
Núñez, M. (2010) · Hepatology · doi:10.1002/hep.23716 · Cited by 178
Nishizawa, H., Iguchi, G., Murawaki, A., Fukuoka, H., Hayashi, Y., Kaji, H., Yamamoto, M., Suda, K., Takahashi, M., Seo, Y., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0252 · Cited by 178
Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., Yamaguchi, S., Ogasawara, N., Katoh, M., Itoh, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19658-7 · Cited by 175
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Mendez-Sanchez, N., Cruz-Ramon, V. C., Ramirez-Perez, O. L., Hwang, J. P., Barranco-Fragoso, B., & Cordova-Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 172
“Unfortunately, pioglitazone has been shown to have secondary effects related to weight gain [133,134].”
BackgroundImpact of Diabetes on the Severity of Liver Disease
Hickman, I. J., & Macdonald, G. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.03.025 · Cited by 175
Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
“The beneficial effects of pioglitazone on hepatic histology have been reported in patients with steatohepatitis, with and without T2DM [206, 207].”
Patel, N. S., Doycheva, I., Peterson, M. R., Hooker, J., Kisselva, T., Schnabl, B., Seki, E., Sirlin, C. B., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.039 · Cited by 173
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D., & Vauthey, J.-N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 173
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
Van Wagner, L. B., Koppe, S. W. P., Brunt, E. M., Gottstein, J., Gardikiotes, K., Green, R. M., & Rinella, M. E. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31539-x · Cited by 173
Gusdon, A. M., Song, K.-X., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 168
“Other studies using pioglitazone have shown that this thiazolidinedione is able to improve hepatic steatosis and markers of inflammation as well as decrease hepatic fibrosis [210, 211].”
A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence
Temple, J., Cordero, P., Li, J., Nguyen, V., & Oben, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060947 · Cited by 171
“Recent research suggests that pioglitazone can improve hepatic steatosis and inflammation, as well as reducing aminotransferase levels and histological evidence of hepatocyte injury in patients with biopsy-proven NASH [24,165,166].”
BackgroundObesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance
Abdelmalek, M. F., & Diehl, A. M. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.001 · Cited by 171
“t al [116] Pioglitazone 26 RCT 12 mo t al [115] Vit E versus vit E þ pioglitazone 21 RCT, open label 6 mo”
BackgroundAssociation of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
Boutari, C., Perakakis, N., & Mantzoros, C. S. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.1.33 · Cited by 167
Zhou, X.-D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K.-C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L.-L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01697-0 · Cited by 168
“Pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, is another glucose-lowering drug that also improves hepatic histology features in patients with biopsy-proven non-alcoholic steatohepatitis, irrespective of the coexistence of T2DM.”
InfluentialWhole body fat: Content and distribution
Thomas, E. L., Fitzpatrick, J. A., Malik, S. J., Taylor-Robinson, S. D., & Bell, J. D. (2013) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2013.04.001 · Cited by 168
“Liver fat has also been shown to be reduced using (1)H MRS following treatment with rosiglitazone [214], pioglitazone [215], metformin [216] and orlistat [116], as well as following weight loss induced by bariatric surgery [217].”
BackgroundKarlas, T., Petroff, D., Garnov, N., Böhm, S., Tenckhoff, H., Wittekind, C., Wiese, M., Schiefke, I., Linder, N., Schaudinn, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091987 · Cited by 168
Sattar, N., Fitchett, D., Hantel, S., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4702-3 · Cited by 168
Chalasani, N. P., Sanyal, A. J., Kowdley, K. V., Robuck, P. R., Hoofnagle, J., Kleiner, D. E., Ünalp, A., & Tonascia, J. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.09.003 · Cited by 168
“Several recent pilot studies have shown encouraging results using the insulin sensitizing thiazolidinediones (TZD) to treat NASH in non-diabetic individuals [26–29].”
MethodResultIL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis
Negrin, K. A., Roth Flach, R. J., DiStefano, M. T., Matevossian, A., Friedline, R. H., Jung, D., Kim, J. K., & Czech, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107265 · Cited by 168
Thiazolidinediones: effects on insulin resistance and the cardiovascular system
Quinn, C. E., Hamilton, P. K., Lockhart, C. J., & McVeigh, G. E. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707452 · Cited by 166
“diabetes and non-alcoholic steatohepatitis treated with pioglitazone (Belfort et al., 2006).”
BackgroundInfluentialCrossan, C., Tsochatzis, E. A., Longworth, L., Gurusamy, K., Davidson, B., Rodríguez-Perálvarez, M., Mantzoukis, K., O’Brien, J., Thalassinos, E., Papastergiou, V., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19090 · Cited by 164
YOUNOSSI, Z. M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03710.x · Cited by 166
Mahady, S. E., Webster, A. C., Walker, S., Sanyal, A., & George, J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.016 · Cited by 165
Wu, X., Zhang, L., Gurley, E., Studer, E., Shang, J., Wang, T., Wang, C., Yan, M., Jiang, Z., Hylemon, P. B., et al. (2008) · Hepatology · doi:10.1002/hep.22239 · Cited by 165
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 165
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yu, Y., Cai, J., She, Z., & Li, H. (2019) · Advanced Science · doi:10.1002/advs.201801585 · Cited by 164
Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Rockey, D. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.011 · Cited by 163
“tion to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg/d) or a hypocaloric diet plus placebo.(81) Compared with placebo, diet plus pioglitazone improved glycemic control and glucose tolerance and led to normalization of”
BackgroundMethodCOX‐2‐mediated Inflammation in Fat Is Crucial for Obesity‐linked Insulin Resistance and Fatty Liver
Hsieh, P., Jin, J., Chiang, C., Chan, P., Chen, C., & Shih, K. (2009) · Obesity · doi:10.1038/oby.2008.674 · Cited by 163
“In fact, thiazolidinediones, an agonist of PPAR-γ and a partial agonist of PPAR-α, have been demonstrated to exert an anti-inflammatory effect (31,35) and used in clinical treatment of NAFLD (36).”
InfluentialColistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections
Bassetti, M., Repetto, E., Righi, E., Boni, S., Diverio, M., Molinari, M. P., Mussap, M., Artioli, S., Ansaldi, F., Durando, P., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm509 · Cited by 163
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Patel Chavez, C., Cusi, K., & Kadiyala, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 162
Self-citationSingh, S., Khera, R., Allen, A. M., Murad, M. H., & Loomba, R. (2015) · Hepatology · doi:10.1002/hep.27999 · Cited by 163
“One RCT of pioglitazone only included patients with diabetes or impaired glucose tolerance.(32) The mean NAFLD activity score at baseline ranged from 3.”
BackgroundFuchs, A., Samovski, D., Smith, G. I., Cifarelli, V., Farabi, S. S., Yoshino, J., Pietka, T., Chang, S.-W., Ghosh, S., Myckatyn, T. M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.05.008 · Cited by 160
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i13.3777 · Cited by 161
Adenosine signaling contributes to ethanol-induced fatty liver in mice
Peng, Z., Borea, P. A., Wilder, T., Yee, H., Chiriboga, L., Blackburn, M. R., Azzena, G., Resta, G., & Cronstein, B. N. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37409 · Cited by 160
Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis
Rakoski, M. O., Singal, A. G., Rogers, M. A. M., & Conjeevaram, H. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04467.x · Cited by 158
“either pioglitazone or rosiglitazone, with a treatment duration of 96 weeks,(25) 48 weeks, 27, 29, 30 or 24 weeks.(28) All six trials excluded patients with benign steatosis and enrolled only patients with NASH.”
BackgroundStål, P. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11077 · Cited by 159
Belfort, R., Berria, R., Cornell, J., & Cusi, K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1487 · Cited by 159
“Both EGP and Rd were calculated as previously reported by our group, as well as an index of hepatic insulin resistance estimated as the product of the fasting EGP and fasting plasma insulin concentration [EGP fasting plasma insulin (mg/kgLBM (lean body mass) 1 min 1 U/ml)] as previously described (20).”
MethodResultSelf-citation
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.